Evidence map›Paper›PMID 26520568›Full record

ArticleRadiation oncology (London, England)2015

Intracranial control after Cyberknife radiosurgery to the resection bed for large brain metastases.

Jennifer Vogel, Eric Ojerholm, Andrew Hollander, Cynthia Briola, Rob Mooij, Michael Bieda, James Kolker, Suneel Nagda, Geoffrey Geiger, Jay Dorsey and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation oncology (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Jennifer VogelDepartment of Radiation Oncology, University of Pennsylvania, TRC-2 West, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA. jennifer.vogel@uphs.upenn.edu.
Eric OjerholmDepartment of Radiation Oncology, University of Pennsylvania, TRC-2 West, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA. Eric.Ojerholm@uphs.upenn.edu.
Andrew HollanderDepartment of Radiation Oncology, University of Pennsylvania, TRC-2 West, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA. Andrew.Hollander@uphs.upenn.edu.
Cynthia BriolaDepartment of Radiation Oncology, Pennsylvania Hospital, Widener Ground Level, 800 Spruce Street, Philadelphia, PA, 19107, USA. Cynthia.Briola@uphs.upenn.edu.
Rob MooijDepartment of Radiation Oncology, Pennsylvania Hospital, Widener Ground Level, 800 Spruce Street, Philadelphia, PA, 19107, USA. Rob.Mooij@uphs.upenn.edu.
Michael BiedaDepartment of Radiation Oncology, Pennsylvania Hospital, Widener Ground Level, 800 Spruce Street, Philadelphia, PA, 19107, USA. Michael.Bieda@uphs.upenn.edu.
James KolkerDepartment of Radiation Oncology, Pennsylvania Hospital, Widener Ground Level, 800 Spruce Street, Philadelphia, PA, 19107, USA. James.Kolker@uphs.upenn.edu.
Suneel NagdaDepartment of Radiation Oncology, Pennsylvania Hospital, Widener Ground Level, 800 Spruce Street, Philadelphia, PA, 19107, USA. Suneel.Nagda@uphs.upenn.edu.
Geoffrey GeigerDepartment of Radiation Oncology, Pennsylvania Hospital, Widener Ground Level, 800 Spruce Street, Philadelphia, PA, 19107, USA. Geoffrey.Geiger@uphs.upenn.edu.
Jay DorseyDepartment of Radiation Oncology, University of Pennsylvania, TRC-2 West, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA. Jay.Dorsey2@uphs.upenn.edu.
Robert LustigDepartment of Radiation Oncology, University of Pennsylvania, TRC-2 West, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA. Robert.Lustig@uphs.upenn.edu.
Donald M O'RourkeDepartment of Neurosurgery, University of Pennsylvania, 3 Silverstein, 3400 Spruce Street, Philadelphia, PA, 19104, USA. Donald.Orourke@uphs.upenn.edu.
Steven BremDepartment of Neurosurgery, University of Pennsylvania, 3 Silverstein, 3400 Spruce Street, Philadelphia, PA, 19104, USA. Steven.Brem@uphs.upenn.edu.
John LeeDepartment of Neurosurgery, University of Pennsylvania, 3 Silverstein, 3400 Spruce Street, Philadelphia, PA, 19104, USA. John.Lee3@uphs.upenn.edu.
Michelle Alonso-BasantaDepartment of Radiation Oncology, University of Pennsylvania, TRC-2 West, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA. Michelle.Alonso-Basanta@uphs.upenn.edu.
University of Pennsylvania · USPennsylvania Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStereotactic radiosurgery (SRS) is an alternative to post-operative whole brain radiation therapy (WBRT) following resection of brain metastases. At our institution, CyberKnife (CK) is considered for local treatment of large cavities ≥2 cm. In this study, we aimed to evaluate patterns of failure and characterize patients best suited to treatment with this approach.

methodsWe retrospectively reviewed 30 patients treated with CK to 33 resection cavities ≥2 cm between 2011 and 2014. Patterns of intracranial failure were analyzed in 26 patients with post-treatment imaging. Survival was estimated by the Kaplan-Meier method and prognostic factors examined with log-rank test and Cox proportional hazards model.

resultsThe most frequent histologies were lung (43 %) and breast (20 %). Median treatment volume was 25.1 cm(3) (range 4.7-90.9 cm(3)) and median maximal postoperative cavity diameter was 3.8 cm (range 2.8-6.7). The most common treatment was 30 Gy in 5 fractions prescribed to the 75 % isodose line. Median follow up for the entire cohort was 9.5 months (range 1.0-34.3). Local failure developed in 7 treated cavities (24 %). Neither cavity volume nor CK treatment volume was associated with local failure. Distant brain failure occurred in 20 cases (62 %) at a median of 4.2 months. There were increased rates of distant failure in patients who initially presented with synchronous metastases (p = 0.02). Leptomeningeal carcinomatosis (LMC) developed in 9 cases, (34 %). Salvage WBRT was performed in 5 cases (17 %) at a median of 5.2 months from CK. Median overall survival was 10.1 months from treatment.

conclusionsThis study suggests that adjuvant CK is a reasonable strategy to achieve local control in large resection cavities. Patients with synchronous metastases at the time of CK may be at higher risk for distant brain failure. The majority of cases were spared or delayed WBRT with the use of local CK therapy.

Indexed as

RadiosurgeryAdultAgedAged, 80 and overBrain NeoplasmsCombined Modality TherapyFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeurosurgical ProceduresProportional Hazards ModelsRetrospective StudiesTreatment Outcome

Identifiers

PMID26520568
PMCPMC4628349
OpenAlexW1961608543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.